We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Imugene Ltd (IMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published: November 2018
Pages: 35
Code: 013BBE115FB440C249D846DCB9E69D0D
Format: PDF
Publisher GlobalData
From Add to basket
$ 250.00

Additonal Information

  • Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene’s lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.
  • provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
  • GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Reasons to buy

Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Add to basket
  • Table of Contents
  • Table of Contents 3
  • List of Tables 4
  • List of Figures 4
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
  • Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
  • Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deal Details 11
  • Partnerships 11
  • Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11
  • Imugene Enters Into Partnership with Medical University of Vienna 12
  • Imugene Enters into Agreement with Novotech 13
  • Licensing Agreements 14
  • Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14
  • Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15
  • Equity Offering 16
  • Imugene to Raise USD6.2 Million in Rights Offering of Shares 16
  • Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17
  • Imugene Raises USD1.6 Million in Rights Offering of Shares 18
  • Imugene Completes First Tranche Of Private Placement Of Shares For US$0.76 Million 19
  • Imugene Completes Rights Offering Of Shares For US$0.19 Million 20
  • Acquisition 21
  • Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21
  • Imugene Ltd - Key Competitors 22
  • Imugene Ltd - Key Employees 23
  • Imugene Ltd - Locations And Subsidiaries 24
  • Head Office 24
  • Other Locations & Subsidiaries 24
  • Recent Developments 25
  • Corporate Communications 25
  • Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board 25
  • Sep 18, 2018: Imugene names Tanios Bekaii - Saab to Scientific Advisory Board 26
  • Aug 23, 2018: Imugene names Dr Mark Marino Chief Medical Officer 27
  • Mar 28, 2018: Leslie Chong Appointed as Managing Director 28
  • Product News 29
  • Jul 23, 2018: Imugene: PD-1 cancer vaccine development update 29
  • 02/12/2018: Novel Anti-PD-1 Mimotope Vaccine Ready for Development 30
  • Clinical Trials 31
  • Feb 13, 2017: Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research 31
  • Other Significant Developments 33
  • Oct 30, 2018: Imugene: Business update – Appendix 4C for the quarter ended 33
  • Jul 31, 2018: Imugene: Business Update - Appendix 4C for the quarter ended 30 June 2018 34
  • Appendix 35
  • Methodology 35
  • About GlobalData 35
  • Contact Us 35
  • Disclaimer 35
  • List of Tables
  • Imugene Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
  • Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
  • Imugene Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
  • Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
  • Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11
  • Imugene Enters Into Partnership with Medical University of Vienna 12
  • Imugene Enters into Agreement with Novotech 13
  • Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14
  • Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15
  • Imugene to Raise USD6.2 Million in Rights Offering of Shares 16
  • Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17
  • Imugene Raises USD1.6 Million in Rights Offering of Shares 18
  • Imugene Completes First Tranche Of Private Placement Of Shares For US$0.76 Million 19
  • Imugene Completes Rights Offering Of Shares For US$0.19 Million 20
  • Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21
  • Imugene Ltd, Key Competitors 22
  • Imugene Ltd, Key Employees 23
  • Imugene Ltd, Subsidiaries 24
  • List of Figures
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
  • Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
  • Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Keywords
;